PPT-DTG/3TC 1st line (GEMINI)

ARV strategies DOR gt DRVr 1st line DRIVEFORWARD W96 DTG monotherapy Switch PIrDTG NEAT22 Switch RPVDTG SWORD Test and Treat DCFTAF DIAMOND 10 noninferiority margin for individual studies. Who We Are. Gemini Skills Workshop. Agenda. Our vision. Our distinct market positioning. Our values. Our organisation. Our way of doing business. Gemini is a new company built around two ideals. Making a Difference:. its . Base Facility at sea. . level; no longer need to trek to the 4,200-m mountain site. National Science Foundation • Division of Astronomical Sciences . Prepared by the . Association of Universities for Research in Astronomy . FLAMINGO. GS-236-0103. ACTG A5257. WAVES. ARIA . Design. Objective. Non inferiority of DTG/ABC/3TC at W48: % HIV RNA < 50 c/mL by intention. to treat, snapshot analysis (lower margin of the 2-sided 95% CI for the difference = - 12%). National Science Foundation • Division of Astronomical Sciences . Prepared by the . Association of Universities for Research in Astronomy . SCIENCE. . PEOPLE TECHNOLOGY. Nearby Exo-Earth Family Withstands Extreme Scrutiny. Who We Are. Gemini Skills Workshop. Agenda. Our vision. Our distinct market positioning. Our values. Our organisation. Our way of doing business. Gemini is a new company built around two ideals. Making a Difference:. ATV/r 300/100 mg QD 3TC 300 mg QD. N = 133. N = 133. Continuación ATV/r 300/100 mg QD 2 NRTI . Diseño. Randomización. 1:1. Etiqueta abierta. Objetivo. Endpoint. primario: proporción de pacientes sin fallo al tratamiento a S48 . STARTMRK. GS-US-236-0102 . SINGLE. Walmsley. S. NEJM 2013;369:1807-18. Design. Objective. Non inferiority of DTG at W48: % HIV RNA < 50 c/mL by intention to treat, snapshot analysis (1-sided significance level of 2.5%, lower margin of . NOAO/. Gemini Data workshop . –. Tucson, 2010. -. 07-20. Marie Lemoine-Busserolle. . Introduction. Hosted by CADC in Victoria, Canada.. Released September 2004. Gemini North data from May 2000. Gemini South data from October 2001. Geneva, March 19 - 20 , 2015 1 | Treatment and Care Team Meg Doherty, Marco Vitoria, Martina Penazzato, Nathan Ford Update on CADO/PADO: what are the challenges in using the current guidelines an WHO HQ. The role of DTG based regimens in first- and second-line HIV treatment and PEP – Updated WHO recommendations. HIV testing and care continuum (2017). Source: UNAIDS/WHO . estimates. 2016 WHO recommandations for 1st Line ART in . nd. 90: Child Friendly Formulations . Victor Musiime, . MBChB. , MMED, PhD. Senior Lecturer, . Makerere. University. Investigator, Joint Clinical Research Centre. Kampala, Uganda. Disclosure statement. –. NAIVE ADULTS WITH HIV-1 INFECTION: 96-WEEK RESULTS FROM THE GEMINI STUDIES. 1. Fundación Huesped, Buenos Aires, Argentina; . 2. Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico; . by Baseline NRTI Resistance . and Second-Line NRTI Use. Dannae. Brown,. 1. . Ruolan. Wang,. 2. Mark Underwood,. 2. Judy Hopking,. 3. Maria Claudia Nascimento,. 4. . Michael Aboud,. 4. . Jörg. 1. ViiV Healthcare, Brentford, UK; . 2. Centre Hospitalier de Tourcoing, Tourcoing, France; . 3. Holdsworth House Medical Brisbane, Queensland, Australia; . 4. CHU Saint-Pierre, Brussels, Belgium; . 5.